Slowed But Not Stalled: The Future of mRNA Vaccine Research

The U.S. government’s abrupt shift in mRNA vaccine research funding has sent shockwaves through the scientific community. In August 2025, the Department of Health and Human Services (HHS) canceled $500 million in funding under the Biomedical Advanced Research and Development Authority (BARDA), ending projects such as Moderna’s Marburg virus vaccine study while allowing some late-stage work, like Arcturus Therapeutics’ influenza vaccine trials, to continue. The move followed years of rapid mRNA vaccine development, including COVID-19 vaccines that prevented over two million deaths in the U.S. alone. The technology’s roots trace back to the 1980s and 1990s, when researchers like Deborah Fuller, now at the University of Washington, pioneered DNA-based vaccines at Agracetus (now PowderJect). Early animal trials showed promise, but human tests in the late 1990s failed, leading many to abandon the field. Fuller persisted, transitioning to RNA vaccines, which gained momentum during COVID-19 as a fast-track platform for emerging threats. The FDA’s role in the funding cuts became clear in February 2026, when it initially rejected an mRNA influenza vaccine application from a company due to concerns over control groups. Two weeks later, the agency reversed its decision, signaling cautious but continued interest. Researchers now fear U.S. disinvestment could stall progress, though Fuller and others argue mRNA’s potential for vaccines and therapeutics remains intact, with breakthroughs likely emerging elsewhere globally. Despite setbacks, mRNA technology’s speed in vaccine development—unmatched by traditional methods—keeps it a critical tool. Before COVID-19, mRNA vaccines were already in clinical trials for prophylactic and therapeutic uses. The funding cuts may slow U.S.-led research, but the field’s adaptability ensures mRNA’s future in public health, even if innovation shifts to international partners.